New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2

doi:10.5306/wjco.v13.i4.276

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5093)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-5) series.

Item

Count

PDF

383

WORD

HTML

2732

Tables (1-5)

265

Sum=3460

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

229

Download

520

Sum=749

Publishing Process of This Article

Item

Count

Browse

298

Download

586

Sum=884

Apr 24, 2022 (publication date) through Sep 21, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Oncol. Apr 24, 2022; 13(4): 276-286
Published online Apr 24, 2022. doi: 10.5306/wjco.v13.i4.276

Table 4 Clinical trials of mesenchymal-epithelial transition factor inhibitors

Drug	Clinical trial	Phase	Treatment	Objective	Status
Glesatinib	NCT02954991	2	Glesatinib + Nivolumab	ORR	Active, not recruiting
Multi-TKI	NCT02954991	2	Glesatinib + Nivolumab	ORR	Active, not recruiting
Glesatinib	NCT02544633	2	Glesatinib	ORR	Completed
Multi-TKI	NCT02544633	2	Glesatinib	ORR	Completed
Merestinib	NCT02920996	2	Merestinib	ORR	Active, not recruiting
Multi-TKI	NCT02920996	2	Merestinib	ORR	Active, not recruiting
Savolitinib	NCT02897479	2	Savolitinib	ORR	Active, not recruiting
Selective-TKI	NCT02897479	2	Savolitinib	ORR	Active, not recruiting
Telisotuzumab (ABBV 399)	NCT03574753	2	ABBV-399	ORR	Completed
MET-mab	NCT03574753	2	ABBV-399	ORR	Completed
JNJ-61186372	NCT02609776	1	JNJ-61186372	ORR, security	Recruiting
EGFR and MET mab	NCT02609776	1	JNJ-61186372	ORR, security	Recruiting

TKI: Tyrosine kinase inhibitor; mab: Monoclonal antibody; ORR: Overall response rate; MET: Mesenchymal-epithelial transition factor; EGFR: Epidermal growth factor receptor.

Citation: Olmedo ME, Cervera R, Cabezon-Gutierrez L, Lage Y, Corral de la Fuente E, Gómez Rueda A, Mielgo-Rubio X, Trujillo JC, Couñago F. New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2. World J Clin Oncol 2022; 13(4): 276-286
URL: https://www.wjgnet.com/2218-4333/full/v13/i4/276.htm
DOI: https://dx.doi.org/10.5306/wjco.v13.i4.276